Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Thiomersal free trivalent influenza split vaccine 2002/2003 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | The subjects in this group will be 18-60 years. |
| Group B | EXPERIMENTAL | The subjects in this group will be \> 60 years. |
| Group C | ACTIVE_COMPARATOR | The subjects in this group will be 18-60 years. |
| Group D | ACTIVE_COMPARATOR | The subjects in this group will be \> 60 years. |
| Name | Type | Description |
|---|---|---|
| Thiomersal free trivalent influenza split vaccine 2002/2003 | BIOLOGICAL | Single dose, intramuscular injection |
| GlaxoSmithKline Biologicals' Influsplit SSW®/Fluarix™ 2002/2003 | BIOLOGICAL | Single dose, intramuscular injection |
Inclusion Criteria: * Healthy subjects who are capable of being vaccinated and subjects with primary diseases (cardiovascular conditions, metabolic conditions such as diabetes mellitus, respiratory diseases) who are capable of being vaccinated and aged over 18 years who want to be vaccinated agains...
Top 8 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 3 | PHASE3 | mRNA Seasonal Flu vaccine, Flu/COVID-19 mRNA combination vaccine |
| Moderna, Inc. | MRNA | 2 | PHASE3 | mRNA-1018-H5, mRNA-1010, Fluarix Trivalent |
| Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | CDTX | 1 | PHASE3 | CD388 |
| Traws Pharma, Inc. | TRAW | 2 | PHASE2 | TRX-100 |
| Sanofi SA Sponsored ADR | SNY | 4 | PHASE1 | H5N8 pandemic influenza vaccine (adjuvanted) |
| Hoffmann-La Roche | RHHBY | 2 | PHASE3 | Baloxavir Marboxil |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD4117, AZD5315 |
| Sinovac Biotech Ltd. | SVA | 1 | PHASE1 | Cell-based Trivalent Split Influenza Virus Vaccine, Egg-based Trivalent Split Influenza Virus Vaccine |
It is an influenza vaccine developed for the prevention of influenza infection. The formulation is a trivalent split vaccine that does not contain thiomersal, and it was evaluated in healthy adult volunteers aged 18 years and older. It is intended for active immunization against seasonal influenza.
The vaccine is developed by GSK plc, which trades under the ticker GSK. GSK conducted the clinical development of this thiomersal free trivalent split influenza vaccine formulation for the 2002/2003 season.
Thiomersal free trivalent influenza split vaccine 2002/2003 is in Phase 3 development. One Phase 3 trial has been completed, and no trials are currently active. The vaccine is investigational and has not been approved by the FDA.
The vaccine was studied in one completed Phase 3 trial, NCT00731029, titled Reacto & Immunogenicity of TF Formulation of Influsplit SSW 2002/03 v/s Std Formulation of Influsplit SSW 2002/03. The trial enrolled 239 participants in Germany, was randomized, double blind, and active controlled, and included healthy volunteers aged 18 years and older.
Yes. The thiomersal free trivalent influenza split vaccine 2002/2003 is the thiomersal free formulation of Influsplit SSW, and it was compared against the standard formulation of Influsplit SSW in the Phase 3 trial NCT00731029.